The treatment will be received by participants of Phase II study at the Okyanos Center for Regenerative Medicine, Freeport, Bahamas.
Rejenevie™ Therapeutics has reportedly announced the initiation of Phase II clinical trial to study the safety and efficacy of its patented AR-100 immune restoration treatment to enhance the function of the aging immune system. The company develops first-in-world stem cell restoration therapies to cure age-related diseases.
Reportedly, the proposed trial protocol of Rejenevie has been approved by the National Stem Cell Ethics Committee of Bahamas. The treatment of approximately 20 patients will be administered and monitored under this protocol. The treatment will be received by participants of Phase II study at the Okyanos Center for Regenerative Medicine, Freeport, Bahamas.
The Phase I trial was completed in February 2019. During the trial, 5 patients were given AR-100 immune restoration treatment of Rejenevie to assess its safety in human patients. There have been no adverse events reported in any of the participants till date.
Dr. Steven Greco, Chief Science Officer at Rejenevie Therapeutics, reportedly stated that the company found the majority of patients have felt a growth in biological killer cell function, which is the measure of the immune system’s ability to attack and kill cancer cells. The company has also seen a dramatic reduction in the number of senescence- and aging-related genes expressed in the patients’ circulating immune cells, he further added.
With the growing age, the functions of immune system diminish with rising vulnerability to diseases related to immune system, including cancer. The aim of AR-100 medical study is to report the decreasing capability of the immune system getting old by a mixed-age (heterochronic) cell culture model to encourage production of transformation factors from new blood cells.
Rejenevie has plans to extend its cell-based therapeutic program beyond age-related diseases to include gene- and cell-based therapies to treat patients with certain types of cancer and infectious disease, among other potential indications.
Source credit: https://www.biospace.com/article/releases/rejenevie-therapeutics-announces-start-of-phase-ii-immune-restoration-treatment-clinical-trial/